Value20242025TTMSelling/general/admin expenses367.82 M275.8 M275.8 MResearch & development322.38 M195.79 M195.79 MOperating income-2.19 B-562.16 M-562.16 MNon-Operating Income, Total26.8 M27.66 M27.66 MInterest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses26.73 M28.65 M28.65 MUnusual income/expense64 K-993 K-993 KPretax income-2.16 B-534.5 M-534.5 MEquity in earnings———Taxes-135.36 M-126.15 M-126.15 MNon-controlling/minority interest———After tax other income/expense-276 K-1.35 M-1.35 MNet income before discontinued operations-2.03 B-408.35 M-408.35 MDiscontinued operations———Net income-2.03 B-408.35 M-408.35 MDilution adjustment———Preferred dividends———Diluted net income available to common stockholders-2.03 B-408.35 M-408.35 MBasic earnings per share (Basic EPS)-63.54-11.11-11.11Diluted earnings per share (Diluted EPS)-63.54-11.11-11.11Average basic shares outstanding31.9 M36.75 M142.98 MDiluted shares outstanding31.9 M36.75 M142.98 MEBITDA-1.9 B-410.26 M-206.06 MEBIT-2.19 B-562.16 M-562.16 MCost of revenue133.89 M332 K—Other cost of goods sold———Depreciation & amortization (cash flow)291.94 M151.9 M356.1 M
GRAIL Inc
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.